Toby Keith's death has raised a lot of questions about stomach cancer, including who it typically affects and how it's treated. Dr. Christopher Cann (Chris Cann, MD), of Fox Chase Cancer Center, shares important information on stomach cancer with Yahoo News: yhoo.it/491vxcn

#ICON : I am sad to see the sudden passing of @ecog colleague, Dr. Edith P. Mitchell, Sidney Kimmel Cancer Center – Jefferson Health. A true #trailblazer ! PLS read about ALL of her #accomplishments . Few women were in GI med onc when I started out, and she was ALWAYS so welcoming to me! #forevergrateful 🙏🏻

Such a loss to the oncology community. I am grateful for her mentorship, and our collaborations. She will be greatly missed 💔

Fantastic 🤩 #womeninGI networking event last night #GI24 ASCO 🙏🏻 Pfizer Oncology Medical for supporting us! Kristen Ciombor Smitha Krishnamurthi Pamela Kunz, MD, FASCO Efrat Dotan MD Nataliya Uboha Pole Doctress, MD 🍉 Carolina Bernabe Shruti Patel, MD and SO many others!!! 🙏🏻🙏🏻 #CancerResearch #cancer

I wasn’t going to post this because knowing Pashtoon Kasi MD, MS he was live tweeting during his excellent Bespoke presentation! 😆😂 Congrats, PK! #ctdna is HERE TO STAY! ASCO #GI24 Natera Weill Cornell Medicine Weill Cornell Medicine Meyer Cancer Center

I am truly honored and flattered by all the tweets and quotes from my #GI24 discussion. I would be doubly flattered if everybody keeps these discussion going. If we want things to change it is up to us to do it and do it now. Thanks everybody.

#GI24 ASCO

I’m a big believer of metastases directed therapy in the truly “OLIGO” metastatic disease.

Careful selection; response to systemic therapy; test of time; #ctDNA ? Multi-D ongoing tumor board discussion is🔑.

👇🏾EXTEND trial results in #PancreasCancer .

OncoAlert

Proud to present our work on the role of geriatric assessments for older adults with GE cancer. We can do better in caring for these patients. #GI24 . Shout out to our talented trainees Dr Lauren Laderman and Meghan Connors. #gerionc , #gastroesophagealcancer ,

Sending this out again! Women and men with a commitment to sponsorship, equality and partnership in GI Oncology, please join us! We Go Together! Pamela Kunz, MD, FASCO Rachna Shroff, MD, FASCO Aparna Kalyan MD

📢 If you're attending #GI24 and are a ♀️ in Onc, friend or ally, this is a must attend event!

Women Excelling in GI Oncology
WE GO TOGETHER
Jan 19, 6:30pm

To register, email [email protected]

So proud to have been part of this study led by the multi-talented Efrat Dotan MD #GI24

Sign up for Fox Chase Cancer Center #soccer shootout Temple Health News Eastern PA Youth Soccer Philly Soccer Page

Dafna is 15 years old.
Ella is 8 years old.
Two little sisters saw their father murdered as they were kidnapped to Gaza.

Releasing the hostages is critical for ceasefire, but time is running out
Don't stay silent
#hamasiISIS .

🔥Nivolumab + low dose ipilimumab as first-line therapy in G/GEJ MSI-H tumor #ESMO23
✅1st results of the NO LIMIT phs-II
👉935 pts screened, 28 pts included, m age 75yrs
👉ORR 62.1%, DCR 79.3%
👉mPFS 13.8, mDOR & OS n.r.
🧐convincing efficacy, no new safety signal
ESMO - Eur. Oncology

🔥Tinengotinib in FGFR2 inhibitor refractory cholangiocarcinoma #ESMO23
✅Phs-II, 73 pts, 47% pts w/ prior FGFRi
👉FGFRi naive: ORR 34% DCR 89.7%, 6 mo
👉prior FGFRi: ORR 38.1%, DCR of 95.2%, mPFS 7 mo
🧐Amazing efficacy in pts w/ prior FGFRi, phs-III for CCA with FGFRi

🔥off the press: Immune Checkpoint Inhibitors for Child-Pugh Class B HCC
JAMA Oncology
doi.org/10.1001/jamaon…
🔎Systematic Review & Meta-Analysis, 22 studies with CP B 699 pts.
👉ICI safe & feasible, but mOS only 5.5 mo
👉some pts may benefit
🧐we need prospective data
ESMO - Eur. Oncology

Oria is 4 years old, and he was taken hostage by the hamas. There is nothing that can justify taking a kid hostage. Nothing!
Being active for releasing the hostages does not mean that you don't support Palestinian - it means that you support humanity.
#HamasisISIS

🔥Nab-paclitaxel + gemcitabine vs mFOLFIRINOX vs S-IROX in #PDAC #ESMO23
✅GENERATE 🇯🇵 phs-II/II, 527 pts
👉ORR 35 vs 32 vs 42
👉mOS 17 vs 14 vs 13.6 mo
👉mPFS 6.7 vs 5.8 vs 6.7
👉 more tox for triplet
🧐phs-3 terminated for futility, control arm outperformed, still a role for

🔥Neoadjuvant short-course radiotherapy followed by camrelizumab + CTX vs long-course CRT followed by CTX in locally advanced rectal cancer #ESMO23
✅UNION phs-III, 231 pts
👉1° EP: pCR 39 vs 15.3%
👉Grade ≥ 3 TRAEs 29.2 vs 27.2%
😅Amazing waterfall blots.. safe & feasible, EFS

🔥Neoadj. FOLFIRINOX vs gemcitabine-based RT for borderline resectable & resectable #PDAC #ESMO23
✅ PREOPANC-2 phs III, 375 pts
👉62% completed FOLFIRINOX, 81% >4 cycles
👉 72% adj Gem
👉moS 21.9 vs 21.3
👉≥3 TEAEs 67% vs 60%
🧐 neoadj. CTx promising, but not yet there...